Bandar Alqarni/X
Sep 29, 2025, 11:36
Bandar Alqarni: Smoflipid 20% Use in IVF Protocols
Bandar Alqarni, Pharmacist in Riyadh, shared a post on X:
“Smoflipid 20% is gaining attention for its off-label use in IVF protocols, especially in cases of Recurrent Implantation Failure (RIF) or Recurrent Pregnancy Loss (RPL).
It may help by:
- Reducing NK cell activity
- Enhancing immune tolerance
- Supporting embryo implantation
While not considered a formal treatment, it is an option in select cases after ruling out organic and chromosomal causes. Its use is under strict medical supervision, often as part of an integrated immunotherapy plan.
Always consult your fertility specialist.”
-
Nov 2, 2026, 17:08Elena Milner: The 2nd Class of the School of Embryology Is Already in Full Swing
-
Nov 2, 2026, 17:05November Is National Diabetes Month – PCOS Awareness Association
-
Nov 2, 2026, 17:04Thanos Papathanasiou: Are We Preparing Patients for the IVF Cycle, or for the IVF Journey?
-
Nov 2, 2026, 17:02Anna Morales: Why Is It So Hard to Build in Women’s Health?
-
Nov 2, 2026, 16:59Rickard Ericsson: Honored to Take on the Role of Interim CEO of the Vitrolife Group
-
Nov 2, 2026, 16:56Mohammed Nasur: 1 Small Simulation, A Bigger Purpose
-
Nov 2, 2026, 16:54Carlos Guerrero: Presenting Our Latest Research on AI and Embryo Assessment at ASRM 2026
-
Nov 2, 2026, 16:52Sarah Lewen: My 1st ASRM Is Officially Complete
-
Nov 2, 2026, 16:49Jemma Garratt: Taking on the Role of Kind IVF and Data Science Manager at London Women’s Clinic
